In a report released yesterday, Chris Shibutani from Cowen & Co. assigned a Buy rating to Seres Therapeutics (NASDAQ: MCRB). The company’s shares opened today at $8.16, close to its 52-week low of $6.65.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 14.2% and a 45.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Seres Therapeutics is Strong Buy and the average price target is $18, representing a 120.6% upside.
In a report issued on May 24, Canaccord Genuity also maintained a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
Based on Seres Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.92 million. In comparison, last year the company had a GAAP net loss of $25.47 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in developing biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
